Daswani B R, Chandanwale A S, Kadam D B, Ghongane B B, Ghorpade V S, Manu H C
Associate Professor, Department of Pharmacology, BJ Government Medical College and Sassoon General Hospitals, Pune, Maharashtra, India.
Dean, BJ Government Medical College and Sassoon General Hospitals, Pune Maharashtra, India.
J Clin Diagn Res. 2017 Sep;11(9):FC17-FC21. doi: 10.7860/JCDR/2017/20132.10670. Epub 2017 Sep 1.
Considering the cost of Anti-Snake Venom (ASV) and irregularity in its supply, there is often a need to curtail doses of ASV, despite guidelines for management of snake bite. During June 2013 to September 2013, when ASV was in short supply, our institutional committee reviewed the overall hospital statistics of snake bite cases as well as scientific literature and formulated a working modified protocol that used low dose of ASV in snake bite cases.
To retrospectively analyse and compare the modified ASV protocol versus conventional ASV protocol with respect to outcome, number of ASV vials required, duration of stay in the hospital/ ICU, and additional supportive interventions needed.
This was a retrospective study conducted at a tertiary care teaching hospital, Maharashtra, India. Hospital records of inpatients admitted for snake bite during June 2013 to September 2013 (since introduction of the modified protocol) as well as during June 2012 to September 2012, (when patients received conventional protocol-historical controls) were retrospectively analysed to assess the number of ASV vials received by the patients during the stay, need for supportive therapy, duration of stay and outcome of the patients.
There was a significant reduction in average number of ASV vials per patient, required vide the modified protocol compared to their historical controls (10.74±0.95 vs 28.17±2.75 p<0.001). There was no significant difference in outcome, need for dialysis, fresh frozen plasma requirement, need for ICU stay and duration of hospitalization of snake bite patients. Yet, the average cost of management of each patient reduced by approximately 11974.41 INR per treated patient, based on the requirement of ASV.
The modified ASV protocol used in this study is more cost effective as compared to the conventional protocol, deserves prospective evaluation and may be followed at least during prime time of scarcity of ASV.
鉴于抗蛇毒血清(ASV)的成本及其供应的不稳定性,尽管有蛇咬伤管理指南,但仍常常需要减少ASV的剂量。在2013年6月至2013年9月期间,当ASV供应短缺时,我们机构的委员会审查了蛇咬伤病例的整体医院统计数据以及科学文献,并制定了一项工作改进方案,在蛇咬伤病例中使用低剂量的ASV。
回顾性分析并比较改进后的ASV方案与传统ASV方案在治疗结果、所需ASV瓶数、住院/重症监护病房(ICU)停留时间以及所需额外支持性干预措施方面的差异。
这是一项在印度马哈拉施特拉邦的三级护理教学医院进行的回顾性研究。对2013年6月至2013年9月(自改进方案引入后)以及2012年6月至2012年9月(患者接受传统方案——历史对照)期间因蛇咬伤入院的住院患者记录进行回顾性分析,以评估患者住院期间接受的ASV瓶数、支持性治疗需求、住院时间和患者的治疗结果。
与历史对照相比,根据改进后的方案,每位患者所需的ASV平均瓶数显著减少(10.74±0.95对28.17±2.75,p<0.001)。蛇咬伤患者的治疗结果、透析需求、新鲜冰冻血浆需求、ICU停留需求和住院时间方面没有显著差异。然而,根据ASV的需求,每位接受治疗患者的平均管理成本降低了约11974.41印度卢比。
本研究中使用的改进后的ASV方案与传统方案相比更具成本效益,值得进行前瞻性评估,并且至少在ASV短缺的高峰期可以采用。